These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 8339249)

  • 1. Analysis of the anti-p53 antibody response in cancer patients.
    Labrecque S; Naor N; Thomson D; Matlashewski G
    Cancer Res; 1993 Aug; 53(15):3468-71. PubMed ID: 8339249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation.
    Winter SF; Minna JD; Johnson BE; Takahashi T; Gazdar AF; Carbone DP
    Cancer Res; 1992 Aug; 52(15):4168-74. PubMed ID: 1322237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer.
    Tilkin AF; Lubin R; Soussi T; Lazar V; Janin N; Mathieu MC; Lefrère I; Carlu C; Roy M; Kayibanda M
    Eur J Immunol; 1995 Jun; 25(6):1765-9. PubMed ID: 7615005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humoral p53 antibody response is a prognostic parameter in ovarian cancer.
    Mayerhofer K; Tempfer C; Kucera E; Hefler L; Zeisler H; Kainz C; Zeillinger R; Sliutz G
    Anticancer Res; 1999; 19(1B):875-8. PubMed ID: 10216509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot.
    Schlichtholz B; Legros Y; Gillet D; Gaillard C; Marty M; Lane D; Calvo F; Soussi T
    Cancer Res; 1992 Nov; 52(22):6380-4. PubMed ID: 1423285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Detection of serum anti-p53 antibodies in patients with various types of cancer].
    Sakai H
    Rinsho Byori; 2002 Jan; 50(1):90-2. PubMed ID: 11871143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 antibodies in patients with various types of cancer: assay, identification, and characterization.
    Lubin R; Schlichtholz B; Teillaud JL; Garay E; Bussel A; Wild CP
    Clin Cancer Res; 1995 Dec; 1(12):1463-9. PubMed ID: 9815945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-P53 antibodies in Brazilian brain tumor patients.
    Fonseca RF; Kawamura MT; Oliveira JA; Teixeira A; Alves G; Carvalho Mda G
    Genet Mol Res; 2003 Jun; 2(2):185-90. PubMed ID: 14966683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prognostic significance of p53 autoantibodies in serum of patients with breast carcinoma].
    Huober J; Sprenger H; Costa SD; Zentgraf H; Schmid H; Kaufmann M; Bastert G
    Zentralbl Gynakol; 1996; 118(10):560-4. PubMed ID: 8999710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [P53 antibodies: a new method for the analysis of alterations of the p53 gene: application to breast cancer].
    Soussi T; Peyrat JP; Lubin R; Bonneterre J
    Pathol Biol (Paris); 1996 Apr; 44(4):232-4. PubMed ID: 8763583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating anti-p53 antibodies in esophageal cancer patients are found predominantly in individuals with p53 core domain mutations in their tumors.
    von Brevern MC; Hollstein MC; Cawley HM; De Benedetti VM; Bennett WP; Liang L; He AG; Zhu SM; Tursz T; Janin N; Trivers GE
    Cancer Res; 1996 Nov; 56(21):4917-21. PubMed ID: 8895744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients.
    Nikitina EY; Clark JI; Van Beynen J; Chada S; Virmani AK; Carbone DP; Gabrilovich DI
    Clin Cancer Res; 2001 Jan; 7(1):127-35. PubMed ID: 11205900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of p53 autoantibodies in sera from glioma patients.
    Rainov NG; Dobberstein KU; Fittkau M; Bahn H; Holzhausen HJ; Gantchev L; Burkert W
    Clin Cancer Res; 1995 Jul; 1(7):775-81. PubMed ID: 9816045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer.
    Hoffmann TK; Donnenberg AD; Finkelstein SD; Donnenberg VS; Friebe-Hoffmann U; Myers EN; Appella E; DeLeo AB; Whiteside TL
    Cancer Res; 2002 Jun; 62(12):3521-9. PubMed ID: 12067999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion.
    Mehta SA; Christopherson KW; Bhat-Nakshatri P; Goulet RJ; Broxmeyer HE; Kopelovich L; Nakshatri H
    Oncogene; 2007 May; 26(23):3329-37. PubMed ID: 17130833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum anti-p53 in relation to mutations across the entire translated p53 gene in colorectal carcinomas.
    Forslund A; Kressner U; Lindmark G; Inganäs M; Lundholm K
    Int J Oncol; 2001 Sep; 19(3):501-6. PubMed ID: 11494027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dominance of wild-type p53-mediated transcriptional activation in breast epithelial cells.
    Davis P; Bazar K; Huper G; Lozano G; Marks J; Iglehart JD
    Oncogene; 1996 Sep; 13(6):1315-22. PubMed ID: 8808706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
    Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
    Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative serum antibodies against the p53 protein in patients with ovarian and endometrial cancer.
    Gadducci A; Ferdeghini M; Buttitta F; Fanucchi A; Annicchiarico C; Prontera C; Bevilacqua G; Genazzani AR
    Anticancer Res; 1996; 16(6B):3519-23. PubMed ID: 9042215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene p53 mutations, protein p53, and anti-p53 antibodies as biomarkers of cancer process.
    Lutz W; Nowakowska-Swirta E
    Int J Occup Med Environ Health; 2002; 15(3):209-18. PubMed ID: 12462448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.